News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Akzo Nobel N.V. Says Asenapine May Be Delayed, Shares Fall
October 18, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
AMSTERDAM, Oct 18 (Reuters) - Dutch chemicals group Akzo Nobel warned of a delay in launching its most promising pipeline drug asenapine and missed quarterly earnings expectations, sending its shares sliding on Wednesday.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
MORE ON THIS TOPIC
Bankruptcy
Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy
June 23, 2026
·
3 min read
·
Gabrielle Masson
Inflammatory bowel disease
Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms
June 23, 2026
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate
Can ADCs be kinder and gentler? Join
BioSpace
at BIO to find out
June 23, 2026
·
3 min read
·
Annalee Armstrong
Lung cancer
Pfizer delivers ‘disappointing’ late-stage lung cancer data for ADC from $43B Seagen buy
June 23, 2026
·
2 min read
·
Tristan Manalac
